Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: II. Cow health and performance in early lactation

A. G. Arruda, S. Godden, P. Rapnicki, P. Gorden, L. Timms, Sharif S Aly, Terry W Lehenbauer, J. Champagne

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The objective of this randomized noninferiority clinical trial was to compare the effect of treatment with 3 different dry cow therapy formulations at dry-off on cow-level health and production parameters in the first 100. d in milk (DIM) in the subsequent lactation, including 305-d mature-equivalent (305ME) milk production, linear score (LS), risk for the cow experiencing a clinical mastitis event, risk for culling or death, and risk for pregnancy by 100 DIM. A total of 1,091 cows from 6 commercial dairy herds in 4 states (California, Iowa, Minnesota, and Wisconsin) were randomly assigned at dry-off to receive treatment with 1 of 3 commercial products: Quartermaster (QT; Zoetis Animal Health, Madison, NJ), Spectramast DC (SP; Zoetis Animal Health) or ToMorrow Dry Cow (TM; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO). All clinical mastitis, pregnancy, culling, and death events occurring in the first 100 DIM were recorded by farm staff using an on-farm electronic record-keeping system. Dairy Herd Improvement Association test-day records of milk production and milk component testing were retrieved electronically. Mixed linear regression analysis was used to describe the effect of treatment on 305ME milk production and LS recorded on the last Dairy Herd Improvement Association test day before 100 DIM. Cox proportional hazards regression analysis was used to describe the effect of treatment on risk for experiencing a case of clinical mastitis, risk for leaving the herd, and risk for pregnancy between calving and 100 DIM. Results showed no effect of treatment on adjusted mean 305ME milk production (QT = 11,759. kg, SP = 11,574. kg, and TM = 11,761. kg) or adjusted mean LS (QT = 1.8, SP = 1.9, and TM = 1.6) on the last test day before 100 DIM. Similarly, no effect of treatment was observed on risk for a clinical mastitis event (QT = 14.8%, SP = 12.7%, and TM = 15.0%), risk for leaving the herd (QT = 7.5%, SP = 9.2%, and TM = 10.3%), or risk for pregnancy (QT = 31.5%, SP = 26.1%, and TM = 26.9%) between calving and 100 DIM.

Original languageEnglish (US)
Pages (from-to)6390-6399
Number of pages10
JournalJournal of Dairy Science
Volume96
Issue number10
DOIs
StatePublished - Oct 2013

Fingerprint

randomized clinical trials
Mastitis
early lactation
Lactation
mastitis
Milk
Randomized Controlled Trials
cows
Health
milk
milk production
Dairy Herd Improvement Associations
pregnancy
culling (animals)
animal health
Pregnancy
calving
regression analysis
herds
testing

Keywords

  • And health
  • Dry cow mastitis
  • Dry cow therapy
  • Milk production

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Food Science
  • Genetics

Cite this

Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations : II. Cow health and performance in early lactation. / Arruda, A. G.; Godden, S.; Rapnicki, P.; Gorden, P.; Timms, L.; Aly, Sharif S; Lehenbauer, Terry W; Champagne, J.

In: Journal of Dairy Science, Vol. 96, No. 10, 10.2013, p. 6390-6399.

Research output: Contribution to journalArticle

@article{6ff5ace407794eb18b67a70c8d6d22c8,
title = "Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: II. Cow health and performance in early lactation",
abstract = "The objective of this randomized noninferiority clinical trial was to compare the effect of treatment with 3 different dry cow therapy formulations at dry-off on cow-level health and production parameters in the first 100. d in milk (DIM) in the subsequent lactation, including 305-d mature-equivalent (305ME) milk production, linear score (LS), risk for the cow experiencing a clinical mastitis event, risk for culling or death, and risk for pregnancy by 100 DIM. A total of 1,091 cows from 6 commercial dairy herds in 4 states (California, Iowa, Minnesota, and Wisconsin) were randomly assigned at dry-off to receive treatment with 1 of 3 commercial products: Quartermaster (QT; Zoetis Animal Health, Madison, NJ), Spectramast DC (SP; Zoetis Animal Health) or ToMorrow Dry Cow (TM; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO). All clinical mastitis, pregnancy, culling, and death events occurring in the first 100 DIM were recorded by farm staff using an on-farm electronic record-keeping system. Dairy Herd Improvement Association test-day records of milk production and milk component testing were retrieved electronically. Mixed linear regression analysis was used to describe the effect of treatment on 305ME milk production and LS recorded on the last Dairy Herd Improvement Association test day before 100 DIM. Cox proportional hazards regression analysis was used to describe the effect of treatment on risk for experiencing a case of clinical mastitis, risk for leaving the herd, and risk for pregnancy between calving and 100 DIM. Results showed no effect of treatment on adjusted mean 305ME milk production (QT = 11,759. kg, SP = 11,574. kg, and TM = 11,761. kg) or adjusted mean LS (QT = 1.8, SP = 1.9, and TM = 1.6) on the last test day before 100 DIM. Similarly, no effect of treatment was observed on risk for a clinical mastitis event (QT = 14.8{\%}, SP = 12.7{\%}, and TM = 15.0{\%}), risk for leaving the herd (QT = 7.5{\%}, SP = 9.2{\%}, and TM = 10.3{\%}), or risk for pregnancy (QT = 31.5{\%}, SP = 26.1{\%}, and TM = 26.9{\%}) between calving and 100 DIM.",
keywords = "And health, Dry cow mastitis, Dry cow therapy, Milk production",
author = "Arruda, {A. G.} and S. Godden and P. Rapnicki and P. Gorden and L. Timms and Aly, {Sharif S} and Lehenbauer, {Terry W} and J. Champagne",
year = "2013",
month = "10",
doi = "10.3168/jds.2013-6705",
language = "English (US)",
volume = "96",
pages = "6390--6399",
journal = "Journal of Dairy Science",
issn = "0022-0302",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations

T2 - II. Cow health and performance in early lactation

AU - Arruda, A. G.

AU - Godden, S.

AU - Rapnicki, P.

AU - Gorden, P.

AU - Timms, L.

AU - Aly, Sharif S

AU - Lehenbauer, Terry W

AU - Champagne, J.

PY - 2013/10

Y1 - 2013/10

N2 - The objective of this randomized noninferiority clinical trial was to compare the effect of treatment with 3 different dry cow therapy formulations at dry-off on cow-level health and production parameters in the first 100. d in milk (DIM) in the subsequent lactation, including 305-d mature-equivalent (305ME) milk production, linear score (LS), risk for the cow experiencing a clinical mastitis event, risk for culling or death, and risk for pregnancy by 100 DIM. A total of 1,091 cows from 6 commercial dairy herds in 4 states (California, Iowa, Minnesota, and Wisconsin) were randomly assigned at dry-off to receive treatment with 1 of 3 commercial products: Quartermaster (QT; Zoetis Animal Health, Madison, NJ), Spectramast DC (SP; Zoetis Animal Health) or ToMorrow Dry Cow (TM; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO). All clinical mastitis, pregnancy, culling, and death events occurring in the first 100 DIM were recorded by farm staff using an on-farm electronic record-keeping system. Dairy Herd Improvement Association test-day records of milk production and milk component testing were retrieved electronically. Mixed linear regression analysis was used to describe the effect of treatment on 305ME milk production and LS recorded on the last Dairy Herd Improvement Association test day before 100 DIM. Cox proportional hazards regression analysis was used to describe the effect of treatment on risk for experiencing a case of clinical mastitis, risk for leaving the herd, and risk for pregnancy between calving and 100 DIM. Results showed no effect of treatment on adjusted mean 305ME milk production (QT = 11,759. kg, SP = 11,574. kg, and TM = 11,761. kg) or adjusted mean LS (QT = 1.8, SP = 1.9, and TM = 1.6) on the last test day before 100 DIM. Similarly, no effect of treatment was observed on risk for a clinical mastitis event (QT = 14.8%, SP = 12.7%, and TM = 15.0%), risk for leaving the herd (QT = 7.5%, SP = 9.2%, and TM = 10.3%), or risk for pregnancy (QT = 31.5%, SP = 26.1%, and TM = 26.9%) between calving and 100 DIM.

AB - The objective of this randomized noninferiority clinical trial was to compare the effect of treatment with 3 different dry cow therapy formulations at dry-off on cow-level health and production parameters in the first 100. d in milk (DIM) in the subsequent lactation, including 305-d mature-equivalent (305ME) milk production, linear score (LS), risk for the cow experiencing a clinical mastitis event, risk for culling or death, and risk for pregnancy by 100 DIM. A total of 1,091 cows from 6 commercial dairy herds in 4 states (California, Iowa, Minnesota, and Wisconsin) were randomly assigned at dry-off to receive treatment with 1 of 3 commercial products: Quartermaster (QT; Zoetis Animal Health, Madison, NJ), Spectramast DC (SP; Zoetis Animal Health) or ToMorrow Dry Cow (TM; Boehringer Ingelheim Vetmedica Inc., St Joseph, MO). All clinical mastitis, pregnancy, culling, and death events occurring in the first 100 DIM were recorded by farm staff using an on-farm electronic record-keeping system. Dairy Herd Improvement Association test-day records of milk production and milk component testing were retrieved electronically. Mixed linear regression analysis was used to describe the effect of treatment on 305ME milk production and LS recorded on the last Dairy Herd Improvement Association test day before 100 DIM. Cox proportional hazards regression analysis was used to describe the effect of treatment on risk for experiencing a case of clinical mastitis, risk for leaving the herd, and risk for pregnancy between calving and 100 DIM. Results showed no effect of treatment on adjusted mean 305ME milk production (QT = 11,759. kg, SP = 11,574. kg, and TM = 11,761. kg) or adjusted mean LS (QT = 1.8, SP = 1.9, and TM = 1.6) on the last test day before 100 DIM. Similarly, no effect of treatment was observed on risk for a clinical mastitis event (QT = 14.8%, SP = 12.7%, and TM = 15.0%), risk for leaving the herd (QT = 7.5%, SP = 9.2%, and TM = 10.3%), or risk for pregnancy (QT = 31.5%, SP = 26.1%, and TM = 26.9%) between calving and 100 DIM.

KW - And health

KW - Dry cow mastitis

KW - Dry cow therapy

KW - Milk production

UR - http://www.scopus.com/inward/record.url?scp=84884352894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884352894&partnerID=8YFLogxK

U2 - 10.3168/jds.2013-6705

DO - 10.3168/jds.2013-6705

M3 - Article

C2 - 23958025

AN - SCOPUS:84884352894

VL - 96

SP - 6390

EP - 6399

JO - Journal of Dairy Science

JF - Journal of Dairy Science

SN - 0022-0302

IS - 10

ER -